Alzinova AB

🌟Alzinova AB reports positive results from the phase 1b extension part of the ALZ-101 study in Alzheimer's disease🌟 We are excited to share positive outcomes from the extension phase of our phase 1b clinical study for ALZ-101, our vaccine candidate targeting Alzheimer’s disease. Key findings include: ✅ Favorable safety and tolerability ✅ A robust and long-lasting immune response, observed in over 95% of patients. ✅ Positive dose-dependent trends in cognitive and functional parameters. These results provide strong momentum as we advance preparations for a phase 2 study. We invite you to join us for a live Q&A session today at 13:00 to learn more about these exciting developments. Together, we’re working toward a future of hope for Alzheimer’s patients and their families. Learn more about the results in the press release, link in comments. ⬇️ #AlzheimerResearch #Innovation #Biotech #ALZ101 #Alzinova

We participated at Carnegies Small Cap day! Yesterday, November 28, Alzinova AB presented at Carnegie's Small Cap Day in Stockholm. Our CEO Tord Labuda shared insights on our innovative treatment for Alzheimer's, the progress of our clinical studies and our plans for the future. Did you miss the event? For our Swedish followers, you can watch our presentation here: https://lnkd.in/damU8dWc #alzheimer #alzheimerresearch

On November 28th, Alzinova AB’s CEO, Tord Labuda, will take the stage at Carnegie's SME Day to share insights about Alzinova and our mission. 🗓️ Date: November 28th ⏰ Time: 16:15 📍 Where: Tune in via the Carnegie live stream, link below Join us as we present our progress in Alzheimer's research and connect with the investor community. Don't miss it! #AlzheimersResearch #InvestorEvent #CarnegieSMEDay #Presentation

Alzinova AB har, under ledning av nye vd Tord Labuda, visionen att positionera sin amyloid-beta oligomer-specifika immunterapi som ett nytt behandlingsalternativ för Alzheimers sjukdom. Bolagets Q3-rapport som släpptes igår, tar ett naturligt avstamp i framstegen som gjorts i år, milstolpar i närtid, samt målet att inleda en fas II-studie under 2025. #lifescience #Alzheimers

Yesterday, Alzinova ABs interim report for January - September 2024 was published! Learn more about our latest achievements in the development of our vaccine candidate ALZ-101 in the ongoing phase 1b study and the overall progress in the company.   Read the full report on our website, link in the comment section.   #InterimReport #AlzheimersResearch #AlzheimersDisease

Exciting times at BIO Europe 2024! Our CEO Tord Labuda and Business Development Director Sebastian Hansson are proudly representing Alzinova AB as we connect with industry leaders and companies.   We are thrilled to share our journey and advancements in addressing Alzheimer’s disease, showcasing our portfolio that have the potential to transforming lives through innovative solutions.   Together, we are shaping the future of healthcare. Let's make a difference! 💡   #BIOEurope2024 #Alzinova #Innovation #Healthcare #AlzheimersResearch

Come meet Alzinova AB at BIO-Europe! Our CEO Tord Labuda and Business Development Director Sebastian Hansson, will be there to promote our two exciting projects; our vaccine candidate ALZ-101 and antibody ALZ-201 against Alzheimer's disease. To explore collaboration and partnership opportunities, send a meeting request through the partnering platform or contact our team via email at info@alzinova.com or send Sebastian a DM here on LinkedIn. We look forward to deepening contacts and exploring collaborations! #BIOEurope #precisionmedicine #innovation #alzheimerresearch #partnering

Den sista dosen av vaccinkandidaten ALZ-101 har nu getts till samtliga patienter som deltar i högdosdelen av Alzinova ABs fas Ib-studie i Alzheimers sjukdom. – Med data från denna studiedel som väntas i början av 2025 är vi ett steg närmare att gå vidare till nästa fas av kliniska prövningar, vilket för oss närmare en behandling av denna förödande sjukdom, säger vd Tord Labuda. #lifescience #Alzheimers

Alzinova AB is pleased to announce that all patients in the high-dose cohort of our phase 1b study for the Alzheimer's vaccine candidate, ALZ-101, have received their final dose. This marks a critical milestone as we continue to explore the potential of our targeted, disease-modifying treatment for Alzheimer’s disease.   With follow-up data from this part of the study expected in early 2025, we are moving closer to advancing to phase 2 and bringing hope to those impacted by this devastating disease.   #Alzheimer #ClinicalTrials #HealthcareInnovation #Biopharma #ALZ101

Our new CEO, Tord Labuda, recently sat down with Redeye analyst Kevin Sule for an insightful "get to know" interview. Tord shares his experience, what he will focus on, his vision for Alzinova AB, and what he’s most looking forward to in the coming year.   The full interview is now available on our website – don’t miss it! 👉 https://lnkd.in/dAFidkpG   #Alzinova #Leadership #AlzheimersResearch #Biotech #Interview #Redeye